DK3180331T3 - POLYMORPHS OF SELINEXOR - Google Patents

POLYMORPHS OF SELINEXOR Download PDF

Info

Publication number: DK3180331T3
Authority: DK; Denmark
Prior art keywords: selinexor; polymorphs
Prior art date: 2014-08-15

Application number

DK15754099.8T

Other languages

Danish (da)

Inventor

Brian Clinton Austad

David G Roe

Original Assignee

Karyopharm Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-15

Filing date

2015-08-14

Publication date

2022-09-12

2015-08-14 Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc

2022-09-12 Application granted granted Critical

2022-09-12 Publication of DK3180331T3 publication Critical patent/DK3180331T3/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

DK15754099.8T 2014-08-15 2015-08-14 POLYMORPHS OF SELINEXOR DK3180331T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462038069P	2014-08-15	2014-08-15
PCT/US2015/045395 WO2016025904A1 (en)	2014-08-15	2015-08-14	Polymorphs of selinexor

Publications (1)

Publication Number	Publication Date
DK3180331T3 true DK3180331T3 (en)	2022-09-12

Family

ID=53969460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15754099.8T DK3180331T3 (en)	2014-08-15	2015-08-14	POLYMORPHS OF SELINEXOR

Country Status (18)

Country	Link
US (6)	US10519139B2 (en)
EP (2)	EP3180331B1 (en)
JP (3)	JP6777626B2 (en)
KR (1)	KR102608259B1 (en)
CN (3)	CN111484483B (en)
AU (4)	AU2015301484B2 (en)
CA (1)	CA2957266A1 (en)
CO (1)	CO2017001884A2 (en)
DK (1)	DK3180331T3 (en)
EA (1)	EA201790384A1 (en)
ES (1)	ES2926377T3 (en)
IL (1)	IL250328B (en)
MA (1)	MA40254B1 (en)
MX (2)	MX388170B (en)
SG (2)	SG10201808624VA (en)
UA (1)	UA123535C2 (en)
WO (1)	WO2016025904A1 (en)
ZA (1)	ZA201700880B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA115532C2 (en)	2011-07-29	2017-11-27	Каріофарм Терапеутікс, Інк.	Hydrazide containing nuclear transport modulators and uses thereof
RS60424B1 (en)	2012-05-09	2020-07-31	Biogen Ma Inc	Nuclear transport modulators and uses thereof
EP2968278B8 (en)	2013-03-15	2019-05-22	Karyopharm Therapeutics Inc.	Methods of promoting wound healing using crm1 inhibitors
CN110183422B (en)	2013-06-21	2023-07-14	卡尔约药物治疗公司	Nuclear transport modulators and uses thereof
CN111484483B (en) *	2014-08-15	2023-05-26	卡尔约药物治疗公司	Polymorphs of Xilinx
WO2017117529A1 (en)	2015-12-31	2017-07-06	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
MA43530A (en)	2015-12-31	2018-11-07	Karyopharm Therapeutics Inc	NUCLEAR TRANSPORT MODULATORS AND THEIR USES
WO2017118940A1 (en)	2016-01-08	2017-07-13	Dr. Reddy's Laboratories Limited	Solid forms of selinexor and process for their preparation
WO2018098472A1 (en)	2016-11-28	2018-05-31	Karyopharm Therapeutics Inc.	Crm1 inhibitors for treating epilepsy
WO2018129227A1 (en)	2017-01-05	2018-07-12	Watson Laboratories Inc.	Novel crystalline forms of selinexor and process for their preparation
CN106831731B (en) *	2017-01-17	2019-11-08	广州市闻皓生物科技有限公司	A kind of synthetic method of Selinexor bulk pharmaceutical chemicals
WO2019232724A1 (en)	2018-06-06	2019-12-12	Xw Laboratories, Inc.	Compounds as nuclear transport modulators and uses thereof
WO2020072008A1 (en) *	2018-10-04	2020-04-09	Deva Holding Anonim Sirketi	Novel solid dispersions of selinexor
JP2022524741A (en) *	2019-03-20	2022-05-10	ジョンソン、マッセイ、パブリック、リミテッド、カンパニー	Co-crystal morphology of serinexol
MA55808A (en) *	2019-05-01	2022-03-09	Karyopharm Therapeutics Inc	METHOD FOR PREPARING XPO1 INHIBITORS AND INTERMEDIATES FOR USE IN PREPARING XPO1 INHIBITORS
EP3968987A4 (en) *	2019-05-16	2022-10-26	Mayo Foundation for Medical Education and Research	METHODS AND SUBSTANCES FOR THE TREATMENT OF CANCER
EP3808742A1 (en)	2019-10-16	2021-04-21	Sandoz AG	Polymorph of selinexor
US20230391754A1 (en)	2020-10-21	2023-12-07	Karyopharm Therapeutics Inc.	Crystalline form of selinexor
CN112679477B (en) *	2020-12-17	2021-10-26	佛山奕安赛医药科技有限公司	Preparation method of celecoxib and intermediate thereof
CA3243305A1 (en) *	2021-12-20	2023-06-29	Rtx Corp	Particle enhancement of ceramic matrix composites, method of manufacture thereof and articles comprising the same
CN116675677B (en) *	2023-08-02	2023-09-26	中国林业科学研究院林产化学工业研究所	C8 urushiol derivative and preparation method and application thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1017398A (en)	1911-01-16	1912-02-13	John E Folsom	Telegraph-key.
KR840000529A (en)	1981-07-07	1984-02-25	콘스탄틴 루이스 클레멘트	Method for preparing indole derivative
CS229934B2 (en)	1981-07-07	1984-07-16	Pfizer	Production method subst.indolylacryte acid derivative
US4778796A (en)	1985-07-19	1988-10-18	Dainippon Pharmaceutical Co., Ltd.	ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en)	1990-02-23	1995-01-24	Takeda Chemical Industries Ltd	4,5,6,7- Tetrahydrothiazolo (5,4-b) pyridine and 5,6-dihydro-4h pyrrolo (3,2-d) thiazolo compounds, their production and pharmaceutical compositions containing them
JP3111321B2 (en)	1990-02-23	2000-11-20	武田薬品工業株式会社	Condensed thiazole compound
US5541213A (en)	1993-06-24	1996-07-30	Eisai Co., Ltd.	Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en)	1994-05-05	1995-11-21	Minnesota Mining And Manufacturing Company	Mist suppressant for solvent extraction metal electrowinning
AU4368996A (en)	1994-11-23	1996-06-17	Neurogen Corporation	Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en)	1995-06-07	2003-01-23	Neurogen Corporation, Corporation Of The State Of Delaware	Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
EP0858457A1 (en)	1995-10-20	1998-08-19	Dr. Karl Thomae GmbH	5-membered heterocycles, pharmaceutical agents containing said compounds and the use thereof and methods of producing them
CN1088711C (en)	1996-04-04	2002-08-07	盐野义制药株式会社	Cephem compound and medicine containing the compound
JP4054992B2 (en)	1996-04-25	2008-03-05	日産化学工業株式会社	Ethylene derivatives and pest control agents
DE69723267T2 (en)	1996-04-25	2004-04-22	Nissan Chemical Industries, Ltd.	ETHYLENE DERIVATIVES AND PESTICIDES
DE19624659A1 (en)	1996-06-20	1998-01-08	Klinge Co Chem Pharm Fab	New pyridylalkene and pyridylalkanoic acid amides
US5994398A (en)	1996-12-11	1999-11-30	Elan Pharmaceuticals, Inc.	Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (en)	1997-12-19	2010-02-17	武田薬品工業株式会社	Anilide derivatives, their production and use
AU2960599A (en)	1998-03-30	1999-10-18	Akira Karasawa	Quinazoline derivatives
US6743585B2 (en)	1999-09-16	2004-06-01	Agilent Technologies, Inc.	Methods for preparing conjugates
CO5271680A1 (en)	2000-02-21	2003-04-30	Smithkline Beecham Corp	COMPOUNDS
EP1335898B1 (en)	2000-09-29	2005-11-23	TopoTarget UK Limited	Carbamic acid compounds comprising an amide linkage as hdac inhibitors
EP1429765A2 (en)	2001-09-14	2004-06-23	Methylgene, Inc.	Inhibitors of histone deacetylase
WO2004037248A2 (en)	2002-10-24	2004-05-06	Carex Sa	Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (en)	2002-10-31	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	New amide compounds having MCH antagonist activity and medicaments containing these compounds
JP4145230B2 (en)	2002-11-01	2008-09-03	武田薬品工業株式会社	Preventive and therapeutic agents for neurological disorders
BR0315815A (en)	2002-11-01	2005-09-13	Takeda Pharmaceutical	Agents for preventing or treating neuropathy, for promoting the production or secretion of a neurotropic factor, for improving pain, neuroprotective and pharmaceutical compound, methods for preventing or treating neuropathy and for promoting the production or secretion of a neurotropic factor. improve pain to protect a nerve in a mammal and produce a compound and use of a compound
CA2504941C (en)	2002-11-08	2012-06-26	Neurogen Corporation	3-substituted-6-aryl pyridines
CA2512886A1 (en)	2003-02-28	2004-09-10	Galderma Research & Development, S.N.C.	Ligands that modulate lxr-type receptors
MY149038A (en)	2004-05-26	2013-07-15	Eisai R&D Man Co Ltd	Cinnamide compound
KR20070050475A (en)	2004-08-11	2007-05-15	교린 세이야꾸 가부시키 가이샤	New Cyclic Amino Benzoate Derivatives
WO2006019020A1 (en)	2004-08-16	2006-02-23	Sankyo Company, Limited	Substituted ureas
EP1849465A4 (en)	2005-02-18	2008-12-24	Takeda Pharmaceutical	AGENT FOR CONTROLLING THE FUNCTION OF THE GPR34 RECEPTOR
WO2007058338A2 (en)	2005-11-15	2007-05-24	Otsuka Pharmaceutical Co., Ltd.	Oxazole compound and pharmaceutical composition
JP2007210929A (en)	2006-02-09	2007-08-23	Sankyo Co Ltd	Medicine containing urea compound
EP1992618B1 (en)	2006-03-09	2012-01-18	Eisai R&D Management Co., Ltd.	Polycyclic cinnamide derivative
ES2452820T3 (en)	2006-04-07	2014-04-02	Methylgene, Inc.	Benzamide derivatives as histone deacetylase inhibitors
NZ572268A (en)	2006-04-18	2011-09-30	Nippon Chemiphar Co	Activating agent for peroxisome proliferator activated receptor delta (ppar)
EP2030974B1 (en)	2006-06-13	2016-02-17	Shanghai Institute of Materia Medica, Chinese Academy of Sciences	Thiazole non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
EP2054411B1 (en)	2006-07-27	2014-08-20	Amorepacific Corporation	Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8273738B2 (en)	2006-09-05	2012-09-25	Kyowa Hakko Kirin Co., Ltd.	Imidazole derivatives
EP1942104A1 (en)	2006-12-20	2008-07-09	sanofi-aventis	Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en)	2006-12-20	2008-07-02	sanofi-aventis	Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
CN101711154A (en)	2007-02-26	2010-05-19	科森生物科学公司	carbamate compound
EP2003118A1 (en)	2007-06-13	2008-12-17	Bayer Schering Pharma Aktiengesellschaft	Cinnamic acid derivatives as modulators of EP2 receptors
EP2323737A2 (en)	2008-08-08	2011-05-25	Synta Pharmaceuticals Corp.	Triazole compounds that modulate hsp90 activity
JP2012532889A (en)	2009-07-09	2012-12-20	クレッシェンドセラピューティクス、エルエルシー	Wound treatment method and scar degeneration method
WO2011069039A1 (en)	2009-12-04	2011-06-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hydrazone and diacyl hydrazine compounds and methods of use
AU2011222531B2 (en)	2010-03-05	2015-03-26	Karyopharm Therapeutics, Inc.	Nuclear transport modulatiors and uses thereof
EP2665362B1 (en)	2011-01-17	2016-03-30	Karyopharm Therapeutics, Inc.	Olefin containing nuclear transport modulators and uses thereof
UA115532C2 (en) *	2011-07-29	2017-11-27	Каріофарм Терапеутікс, Інк.	Hydrazide containing nuclear transport modulators and uses thereof
MX350442B (en)	2011-07-29	2017-09-06	Karyopharm Therapeutics Inc	Nuclear transport modulators and uses thereof.
WO2013020024A2 (en)	2011-08-03	2013-02-07	Karyopharm Therapeutics, Inc.	Maleimide compounds and methods of treatment
RS60424B1 (en)	2012-05-09	2020-07-31	Biogen Ma Inc	Nuclear transport modulators and uses thereof
EP2968278B8 (en) *	2013-03-15	2019-05-22	Karyopharm Therapeutics Inc.	Methods of promoting wound healing using crm1 inhibitors
US20160016916A1 (en)	2013-03-15	2016-01-21	Karyopharm Therapeutics Inc.	Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
WO2014205393A1 (en)	2013-06-21	2014-12-24	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
CN110183422B (en)	2013-06-21	2023-07-14	卡尔约药物治疗公司	Nuclear transport modulators and uses thereof
US11567063B2 (en) *	2013-11-15	2023-01-31	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Methods for assessing cell viability or predicting cell response to a treatment using cell movement
US10969391B2 (en)	2014-07-11	2021-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing hematological cancers
WO2016015597A1 (en) *	2014-07-26	2016-02-04	Sunshine Lake Pharma Co., Ltd.	Compounds as cdk small-molecule inhibitors and uses thereof
CN111484483B (en)	2014-08-15	2023-05-26	卡尔约药物治疗公司	Polymorphs of Xilinx
WO2017040311A1 (en)	2015-08-28	2017-03-09	The Trustees Of Columbia University In The City Of New York	Systems and methods for matching oncology signatures
MA43530A (en)	2015-12-31	2018-11-07	Karyopharm Therapeutics Inc	NUCLEAR TRANSPORT MODULATORS AND THEIR USES
WO2017117529A1 (en)	2015-12-31	2017-07-06	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
WO2017118940A1 (en)	2016-01-08	2017-07-13	Dr. Reddy's Laboratories Limited	Solid forms of selinexor and process for their preparation
JP6765198B2 (en)	2016-03-10	2020-10-07	パナソニック株式会社	Latent heat storage material and heat storage system using it
WO2018098472A1 (en)	2016-11-28	2018-05-31	Karyopharm Therapeutics Inc.	Crm1 inhibitors for treating epilepsy
WO2018129227A1 (en) *	2017-01-05	2018-07-12	Watson Laboratories Inc.	Novel crystalline forms of selinexor and process for their preparation
CN106831731B (en)	2017-01-17	2019-11-08	广州市闻皓生物科技有限公司	A kind of synthetic method of Selinexor bulk pharmaceutical chemicals
CA3131720A1 (en)	2019-03-27	2020-10-01	Andrea Califano	Biomarkers for selinexor
EP3808742A1 (en)	2019-10-16	2021-04-21	Sandoz AG	Polymorph of selinexor
US11828455B2 (en)	2019-12-06	2023-11-28	Bae Systems Plc	Light source
US20230391754A1 (en)	2020-10-21	2023-12-07	Karyopharm Therapeutics Inc.	Crystalline form of selinexor

2015
- 2015-08-14 CN CN202010093491.4A patent/CN111484483B/en active Active
- 2015-08-14 EA EA201790384A patent/EA201790384A1/en unknown
- 2015-08-14 MA MA40254A patent/MA40254B1/en unknown
- 2015-08-14 AU AU2015301484A patent/AU2015301484B2/en active Active
- 2015-08-14 SG SG10201808624VA patent/SG10201808624VA/en unknown
- 2015-08-14 JP JP2017508087A patent/JP6777626B2/en active Active
- 2015-08-14 CN CN202010093239.3A patent/CN111481553B/en active Active
- 2015-08-14 UA UAA201702169A patent/UA123535C2/en unknown
- 2015-08-14 CN CN201580056017.1A patent/CN107072992B/en active Active
- 2015-08-14 MX MX2017002013A patent/MX388170B/en unknown
- 2015-08-14 DK DK15754099.8T patent/DK3180331T3/en active
- 2015-08-14 CA CA2957266A patent/CA2957266A1/en active Pending
- 2015-08-14 US US15/503,319 patent/US10519139B2/en active Active
- 2015-08-14 EP EP15754099.8A patent/EP3180331B1/en active Active
- 2015-08-14 ES ES15754099T patent/ES2926377T3/en active Active
- 2015-08-14 WO PCT/US2015/045395 patent/WO2016025904A1/en not_active Ceased
- 2015-08-14 EP EP22176543.1A patent/EP4112615A1/en active Pending
- 2015-08-14 SG SG11201700789SA patent/SG11201700789SA/en unknown
- 2015-08-14 KR KR1020177006680A patent/KR102608259B1/en active Active
2017
- 2017-01-29 IL IL250328A patent/IL250328B/en unknown
- 2017-02-03 ZA ZA2017/00880A patent/ZA201700880B/en unknown
- 2017-02-14 MX MX2021014128A patent/MX2021014128A/en unknown
- 2017-02-24 CO CONC2017/0001884A patent/CO2017001884A2/en unknown
2019
- 2019-11-11 US US16/679,630 patent/US11078190B2/en active Active
2020
- 2020-05-19 AU AU2020203246A patent/AU2020203246B2/en active Active
- 2020-05-29 JP JP2020093874A patent/JP7218323B2/en active Active
2021
- 2021-07-01 US US17/365,656 patent/US11807629B2/en active Active
- 2021-12-14 AU AU2021286266A patent/AU2021286266B2/en active Active
2023
- 2023-01-25 JP JP2023009361A patent/JP7558310B2/en active Active
- 2023-04-05 US US18/131,273 patent/US11753401B2/en active Active
- 2023-04-07 US US18/132,241 patent/US11746102B2/en active Active
- 2023-07-26 US US18/226,570 patent/US12371420B2/en active Active
2024
- 2024-04-30 AU AU2024202835A patent/AU2024202835A1/en active Pending

Also Published As

Publication number	Publication date
US20230242517A1 (en)	2023-08-03
US20180215733A1 (en)	2018-08-02
WO2016025904A1 (en)	2016-02-18
CN111481553A (en)	2020-08-04
CN107072992B (en)	2020-03-10
NZ728850A (en)	2024-03-22
JP6777626B2 (en)	2020-10-28
JP2017527549A (en)	2017-09-21
IL250328A0 (en)	2017-03-30
CN107072992A (en)	2017-08-18
US11807629B2 (en)	2023-11-07
ES2926377T3 (en)	2022-10-25
JP2023052622A (en)	2023-04-11
JP2020143144A (en)	2020-09-10
EP3180331B1 (en)	2022-06-08
IL250328B (en)	2022-05-01
EA201790384A1 (en)	2017-08-31
KR102608259B1 (en)	2023-11-29
US12371420B2 (en)	2025-07-29
CN111481553B (en)	2023-09-01
MX2017002013A (en)	2017-05-12
KR20170043561A (en)	2017-04-21
CN111484483A (en)	2020-08-04
AU2015301484B2 (en)	2020-02-20
US11746102B2 (en)	2023-09-05
CO2017001884A2 (en)	2017-07-19
AU2020203246B2 (en)	2021-09-16
AU2024202835A1 (en)	2024-05-23
US11078190B2 (en)	2021-08-03
AU2021286266A1 (en)	2022-01-06
AU2015301484A1 (en)	2017-03-02
AU2020203246A1 (en)	2020-06-04
SG10201808624VA (en)	2018-11-29
CA2957266A1 (en)	2016-02-18
SG11201700789SA (en)	2017-02-27
US11753401B2 (en)	2023-09-12
US20200283419A1 (en)	2020-09-10
US20230242516A1 (en)	2023-08-03
MX388170B (en)	2025-03-19
US10519139B2 (en)	2019-12-31
MX2021014128A (en)	2022-01-04
US20220135545A1 (en)	2022-05-05
CN111484483B (en)	2023-05-26
JP7558310B2 (en)	2024-09-30
AU2021286266B2 (en)	2024-02-01
ZA201700880B (en)	2020-01-29
US20240208943A1 (en)	2024-06-27
MA40254A (en)	2021-05-19
EP4112615A1 (en)	2023-01-04
UA123535C2 (en)	2021-04-21
MA40254B1 (en)	2022-09-30
JP7218323B2 (en)	2023-02-06
EP3180331A1 (en)	2017-06-21

Publication	Publication Date	Title
DK3180331T3 (en)	2022-09-12	POLYMORPHS OF SELINEXOR
DK3137169T3 (en)	2022-02-14	INHIBITORIES OF LYSIN-SPECIFIC DEMETHYLASE-1
DK3134530T3 (en)	2019-09-09	TREATMENT OF HYPERBILIR RUBINY
DK3102576T3 (en)	2019-07-22	DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA
DK3192902T3 (en)	2019-07-15	PROCEDURE FOR THE MANUFACTURE OF GRAPHENCY VISCOSEFIBREES
DK3201410T3 (en)	2022-02-21	IMPROVEMENTS OF BUILDING COVERINGS
DK3164380T3 (en)	2022-03-28	INHIBITORS OF LIGHT-SPECIFIC DEMETHYLASE-1
DK3514109T3 (en)	2021-05-25	HYDROPYROLYSE OF BIOMASSIC RAW MATERIALS
DK3117030T3 (en)	2022-06-27	DIAGNOSIS OF SEPSIS
DK3558961T3 (en)	2021-04-12	Polymorphs
DK3558995T3 (en)	2023-10-02	Polymorphs
DK3233813T3 (en)	2022-03-07	PROCEDURES FOR THE PREPARATION OF OXATHIAZINE-LIKE COMPOUNDS
DK3132009T3 (en)	2023-02-06	COURSE OF ACTION
DK3220891T3 (en)	2019-11-04	SUBLINGUAL FORMULATION OF RILUZOL
DK3283210T3 (en)	2021-11-22	COURSE OF ACTION
DK3204352T3 (en)	2020-09-28	Inhibitors of lysine-gingipain
DK3418273T3 (en)	2022-03-21	Derivatives of flavaglines
DK3511000T3 (en)	2022-05-30	CRYSTALLINIC FORM X2 OF GRAPIPRANT
DK3297619T3 (en)	2022-08-15	Therapeutic uses of L-4-chlorokynurenine
DK3368044T3 (en)	2021-09-13	TREATMENT OF HEPATIC STEATOSE-RELATED OLIGO-OVULATION
DK3201323T3 (en)	2020-02-03	Modification of bacteriophage
IL254502A0 (en)	2017-11-30	Solid forms of menaquinols
DK3137449T3 (en)	2020-03-02	METHODS OF PREPARING SUBSTITUTED CYCLOSERINES
DK2910535T3 (en)	2019-07-01	COMPOSITION FOR USE OF EXPANDED PERLIT
DK3430004T3 (en)	2020-09-28	SOLID FORMS OF NILOTINE INSALTS